BioCentury
ARTICLE | Clinical News

TD139: Phase I/IIa started

October 13, 2014 7:00 AM UTC

Galecto began a double-blind, placebo-controlled, U.K. Phase I/IIa trial of inhaled TD139 in up to 36 healthy male volunteers and up to 24 patients with IPF. The Phase I part will evaluate single asce...